The final result of the COSMIC-313 trial is not the only disappointment for Exelixis. Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The ...
February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback